免責事項: 本サイトは、FDA、ClinicalTrials.gov、PubMed、SEC EDGAR などの公式公開データを一般参考用に集約するものであり、医学的助言、診断、治療推奨、投資助言を構成しません。

臨床試験

Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis

NCT: NCT07583342 · ENROLLING_BY_INVITATION

NCT識別子NCT07583342
ステータスENROLLING_BY_INVITATION
開始日2025-12-08
SponsorNorthwell Health (OTHER)
First posted
Last updated

概要

The goal of this study is to learn if Relizorb, a fat-digesting enzyme, can improve tolerance of tube feeds in adult patients with moderate to severe pancreatitis. The main question it aims to answer is: Does Relizorb allow more nutrition to be delivered to participants than they received without it? Participants will be observed with standard, universal monitoring after adding Relizorb to their nutrition regimen.

公式ソース

ClinicalTrials.govで見る →

データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。

↑